Tech Company Financing Transactions

Intarcia Therapeutics Funding Round

Intarcia Therapeutics, based in Boston, raised $210 million from Farallon Capital Management, New Enterprise Associates and New Leaf Venture Partners.

Transaction Overview

Company Name
Intarcia Therapeutics
Announced On
11/16/2012
Transaction Type
Debt
Venture Equity
Amount
$210,000,000
Round
Undisclosed
Investors

Farallon Capital Management

New Enterprise Associates (Ed Mathers)

New Leaf Venture Partners (James Niedel)

The Baupost Group

Venrock (Bryan Roberts)

Proceeds Purpose
As a result of these transactions, Intarcia has retained full strategic and financial control of its lead product candidate ITCA 650 (continuous subcutaneous delivery of exenatide), which, if approved, would be the first and only once-yearly, injection-free GLP-1 therapy for the treatment of type 2 diabetes. Intarcia intends to initiate the global Phase 3 program for ITCA 650 in the first quarter of 2013 with its strategic partner Quintiles, Inc., the world's leading biopharmaceutical service provider, which has helped develop or commercialize 18 of the 20 best-selling diabetes products.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Phone
(617) 936-2500
Website
www.intarcia.com
Email Address
[email protected]
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Intarcia Therapeutics LinkedIn Company Profile
Social Media
Intarcia Therapeutics Company Twitter Account
Company News
Intarcia Therapeutics News
Facebook
Intarcia Therapeutics on Facebook
YouTube
Intarcia Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
  Kurt Graves LinkedIn Profile  Kurt Graves Twitter Account  Kurt Graves News  Kurt Graves on Facebook
Chief Scientific Officer
Andrew Young
  Andrew Young LinkedIn Profile  Andrew Young Twitter Account  Andrew Young News  Andrew Young on Facebook
VP - Client Services
Jay Smith
  Jay Smith LinkedIn Profile  Jay Smith Twitter Account  Jay Smith News  Jay Smith on Facebook
VP - General Counsel
Raymond Keane
  Raymond Keane LinkedIn Profile  Raymond Keane Twitter Account  Raymond Keane News  Raymond Keane on Facebook
VP - Human Resources
James Brady
  James Brady LinkedIn Profile  James Brady Twitter Account  James Brady News  James Brady on Facebook
VP - Manufacturing
Thomas Alessi
  Thomas Alessi LinkedIn Profile  Thomas Alessi Twitter Account  Thomas Alessi News  Thomas Alessi on Facebook

 

 

Browse more venture capital transactions:

Prev: 11/16/2012: UpThere venture capital transaction
Next: 11/16/2012: CityScan venture capital transaction

 

Share this article

 

News on VC Transactions

Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.